Current and emerging treatment options for Peyronie's disease

Open Access Journal of Urology

Volumn 5, Issue 1, 2013, Pages 17-27

  Gokce, Ahmet ^a   Wang, Julie C ^a   Powers, Mary K ^a   Hellstrom, Wayne J G ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Extracorporeal shockwave therapy; Incision and grafting; Intralesional treatment; Oral therapy; Penile prosthesis; Plication; Topical therapy; Traction devices

Indexed keywords

3 AMINOPROPIONITRILE; 4 AMINOBENZOATE POTASSIUM; ALPHA TOCOPHEROL; CARNITINE; COLCHICINE; COLLAGENASE; CORTICOSTEROID; DEXAMETHASONE; HYDROCORTISONE; INTERFERON; LEVACECARNINE; PENTOXIFYLLINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROPIONYLCARNITINE; SILDENAFIL; TADALAFIL; TAMOXIFEN; TOCOPHEROL; VERAPAMIL;

ARTHRALGIA; ATROPHY; CHILL; CLINICAL EFFECTIVENESS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; ERECTILE DYSFUNCTION; EUPHORIA; EXTRACORPOREAL LITHOTRIPSY; FEVER; FIBROSIS; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; IMMUNE DEFICIENCY; INCISION; IONTOPHORESIS; LOW DRUG DOSE; NAUSEA; PAIN; PENILE SWELLING; PENIS PROSTHESIS; PEYRONIE DISEASE; REVIEW; SIDE EFFECT; SINUSITIS; SURGICAL APPROACH; TISSUE GRAFT; TREATMENT DURATION; TREATMENT PLANNING; VOMITING;

EID: 84872872469     PISSN: None     EISSN: 11791551     Source Type: Journal    
DOI: None     Document Type: Review

References (121)

1. Mulhall JP, Creech SD, Boorjian SA, et al. Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J Urol. 2004;171:2350-2353.
2. Bella AJ, Perelman MA, Brant WO, Lue TF. Peyronie's disease (CME). J Sex Med. 2007;4:1527-1538.
3. Taylor FL, Levine LA. Peyronie's Disease. Urol Clin North Am. 2007;34:517-534. vi.
4. Rosen R, Catania J, Lue T, et al. Impact of Peyronie's disease on sexual and psychosocial functioning: qualitative findings in patients and controls. J Sex Med. 2008;5:1977-1984.
5. Chung E, De Young L, Brock GB. Rat as an animal model for Peyronie's disease research: a review of current methods and the peer-reviewed literature. Int J Impot Res. 2011;23:235-241.
6. Usta MF, Bivalacqua TJ, Jabren GW, et al. Relationship between the severity of penile curvature and the presence of comorbidities in men with Peyronie's disease. J Urol. 2004;171:775-779.
7. Bjekic MD, Vlajinac HD, Sipetic SB, Marinkovic JM. Risk factors for Peyronie's disease: a case-control study. BJU Int. 2006;97:570-574.
8. Kadioglu A, Tefekli A, Erol B, Oktar T, Tunc M, Tellaloglu S. A retrospective review of 307men with Peyronie's disease. J Urol. 2002;168:1075-1079.
9. El-Sakka AI, Hassoba HM, Chui RM, Bhatnagar RS, Dahiya R, Lue TF. An animal model of Peyronie's-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J Urol. 1997;158:2284-2290.
10. Del Carlo M, Cole AA, Levine LA. Differential calcium independent regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by interleukin-1beta and transforming growth factor-beta in Peyronie's plaque fibroblasts. J Urol. 2008;179:2447-2455.
11. Gonzalez-Cadavid NF, Rajfer J. Treatment of Peyronie's disease with PDE5inhibitors: an antifibrotic strategy. Nat Rev Urol. 2010;7:215-221.
12. Lin CS, Lin G, Wang Z, Maddah SA, Lue TF. Upregulation of monocyte chemoattractant protein 1 and effects of transforming growth factor-beta 1in Peyronie's disease. Biochem Biophys Res Commun. 2002;295:1014-1019.
13. Hellstrom WJ. Medical management of Peyronie's disease. J Androl. 2009;30:397-405.
14. Gelbard MK, Dorey F, James K. The natural history of Peyronie's disease. J Urol. 1990;144:1376-1379.
15. Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie's disease. J Urol. 2006;175:2115-2118; discussion 2118.
16. Ralph D, Gonzalez-Cadavid N, Mirone V, et al. The management of Peyronie's disease: evidence-based 2010guidelines. J Sex Med. 2010;7:2359-2374.
17. Montorsi F, Adaikan G, Becher E, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med. 2010;7:3572-3588.
18. Gur S, Limin M, Hellstrom WJ. Current status and new developments in Peyronie's disease: medical, minimally invasive and surgical treatment options. Expert Opin Pharmacother. 2011;12:931-944.
19. Ahuja SK, Sikka SC, Hellstrom WJ. Stimulation of collagen production in an in vitro model for Peyronie's disease. Int J Impot Res. 1999;11:207-212.
20. Safarinejad MR, Hosseini SY, Kolahi AA. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study. J Urol. 2007;178:1398-1403; discussion 1403.
21. Shindel AW, Bullock TL, Brandes S. Urologist practice patterns in the management of Peyronie's disease: a nationwide survey. J Sex Med. 2008;5:954-964.
22. Zarafonetis CJ, Horrax TM. Treatment of Peyronie's disease with potassium para-aminobenzoate (potaba). J Urol. 1959;81:770-772.
23. Trost LW, Gur S, Hellstrom WJ. Pharmacological Management of Peyronie's Disease. Drugs. 2007;67:527-545.
24. Shah PJR GN, Adib RS, Pryor JP. A multicentre double-blind controlled clinical trial of potassium-paraaminobenzoate (Potaba) in Peyronie's disease. Prog Reprod Biol Med. 1983;61-67.
25. Weidner W, Hauck EW, Schnitker J. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. Eur Urol. 2005;47:530-535; discussion 535-536.
26. Akkus E, Carrier S, Rehman J, Breza J, Kadioglu A, Lue TF. Is colchicine effective in Peyronie's disease? A pilot study. Urology. 1994;44:291-295.
27. Kadioglu A, Tefekli A, Koksal T, Usta M, Erol H. Treatment of Peyronie's disease with oral colchicine: long-term results and predictive parameters of successful outcome. Int J Impot Res. 2000;12:169-175.
28. Prieto Castro RM, Leva Vallejo ME, Regueiro Lopez JC, et al. Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease. BJU Int. 2003;91:522-524.
29. Akman T, Sanli O, Uluocak N, et al. The most commonly altered type of Peyronie's disease deformity under oral colchicine treatment is lateral curvature that mostly shifts to the dorsal side. Andrologia. 2011;43:28-33.
30. Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study. Int J Impot Res. 2004;16:238-243.
31. Apaydin E, Semerci B, Kefi A, Cikili N, Gursan A, Mulazimoglu N. The use of tamoxifen in the treatment of Peyronie's disease. Int J Impot Res. 1998;10:S57.
32. Ralph DJ, Brooks MD, Bottazzo GF and Pryor JP. The treatment of Peyronie's disease with tamoxifen. Br J Urol. 1992;70:648-651.
33. Teloken C, Rhoden EL, Grazziotin TM, Ros CT, Sogari PR, Souto CA. Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol. 1999;162:2003-2005.
34. Smith JF, Walsh TJ, Lue TF. Peyronie's disease: a critical appraisal of current diagnosis and treatment. Int J Impot Res. 2008;20:445-459.
35. Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU Int. 2001;88:63-67.
36. Cavallini G, Biagiotti G, Koverech A, Vitali G. Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease. BJU Int. 2002;89:895-900.
37. Karlic H, Lohninger A. Supplementation of L-carnitine in athletes: does it make sense? Nutrition. 2004;20:709-715.
38. Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide. 2003;9:229-244.
39. Smith JF, Shindel AW, Huang YC, et al. Pentoxifylline treatment and penile calcifications in men with Peyronie's disease. Asian J Androl. 2011;13:322-325.
40. Shindel AW, Lin G, Ning H, et al. Pentoxifylline attenuates transforming growth factor-beta1-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrix. J Sex Med. 2010;7:2077-2085.
41. Lin G, Shindel AW, Banie L, et al. Pentoxifylline attenuates transforming growth factor-beta1-stimulated elastogenesis in human tunica albuginea-derived fibroblasts part 2: Interference in a TGF-beta1/Smad-dependent mechanism and downregulation of AAT1. J Sex Med. 2010;7:1787-1797.
42. Safarinejad MR, Asgari MA, Hosseini SY, Dadkhah F. A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie's disease. BJU Int. 2010;106:240-248.
43. Levine LA, Latchamsetty KC. Treatment of erectile dysfunction in patients with Peyronie's disease using sildenafil citrate. Int J Impot Res. 2002;14:478-482.
44. Levine LA, Greenfield JM, Estrada CR. Erectile dysfunction following surgical correction of Peyronie's disease and a pilot study of the use of sildenafil citrate rehabilitation for postoperative erectile dysfunction. J Sex Med. 2005;2:241-247.
45. Ferrini MG, Kovanecz I, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease. BJU Int. 2006;97:625-633.
46. Chung E, Deyoung L, Brock GB. The role of PDE5inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. J Sex Med. 2011;8:1472-1477.
47. Palmieri A, Imbimbo C, Creta M, Verze P, Fusco F, Mirone V. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial. Int J Androl. 2011.
48. Tranchant C, Braun S, Warter JM. [Mechanism of action of glucocorticoids: role of lipocortins]. Rev Neurol (Paris). 1989;145:813-818.
49. Bodner H, Howard AH, Kaplan JH. Peyronle's disease: cortisone-hyaluronidase-hydrocortisone therapy. J Urol. 1954;72:400-403.
50. Winter CC, Khanna R. Peyronie's disease: results with dermo-jet injection of dexamethasone. J Urol. 1975;114:898-900.
51. Williams G, Green NA. The non-surgical treatment of Peyronie's disease. Br J Urol. 1980;52:392-395.
52. Cipollone G, Nicolai M, Mastroprimiano G, Iantorno R, Longeri D, Tenaglia R. [Betamethasone versus placebo in Peyronie's disease]. Arch Ital Urol Androl. 1998;70:165-168.
53. Gelbard MK, Walsh R, Kaufman JJ. Collagenase for Peyronie's disease experimental studies. Urol Res. 1982;10:135-140.
54. Gelbard MK, Lindner A, Kaufman JJ. The use of collagenase in the treatment of Peyronie's disease. J Urol. 1985;134:280-283.
55. Hamilton RG, Mintz GR, Gelbard MK. Humoral immune responses in Peyronie's disease patients receiving clostridial collagenase therapy. J Urol. 1986;135:641-647.
56. Gelbard MK, James K, Riach P, Dorey F. Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study. J Urol. 1993;149:56-58.
57. Jordan GH. The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, single-center, non-placebo-controlled study. J Sex Med. 2008;5:180-187.
58. Roth M, Eickelberg O, Kohler E, Erne P, Block LH. Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci USA. 1996;93:5478-5482.
59. Mulhall JP, Anderson MS, Lubrano T, Shankey TV. Peyronie's disease cell culture models: phenotypic, genotypic and functional analyses. Int J Impot Res. 2002;14:397-405.
60. Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol. 1994;151:1522-1524.
61. Lasser A, Vandenberg TL, Vincent MJ, Hellstrom WJ. Intraplaque verapamil injection for treatment of Peyronie's disease. J La State Med Soc. 1998;150:431-434.
62. Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie's disease. J Urol. 2002;168:621-625; discussion 625-626.
63. Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study. Urology. 1998;51:620-626.
64. Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha,-beta and-gamma. Scand J Urol Nephrol. 1991;25:89-94.
65. Polat O, Gul O, Ozbey I, Ozdikici M, Bayraktar Y. Peyronie's disease: intralesional treatment with interferon alpha-2A and evaluation of the results by magnetic resonance imaging. Int Urol Nephrol. 1997;29:465-471.
66. Ahuja S, Bivalacqua TJ, Case J, Vincent M, Sikka SC, Hellstrom WJ. A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie's disease. J Androl. 1999;20:444-448.
67. Astorga R, Cantero O, Contreras D, et al. Intralesional recombinant interferon alpha-2b in Peyronie's disease. Arch Esp Urol. 2000;53:665-671.
68. Brake M, Loertzer H, Horsch R, Keller H. Treatment of Peyronie's disease with local interferon-alpha 2b. BJU Int. 2001;87:654-657.
69. Judge IS, Wisniewski ZS. Intralesional interferon in the treatment of Peyronie's disease: a pilot study. Br J Urol. 1997;79:40-42.
70. Hellstrom WJ, Kendirci M, Matern R, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. J Urol. 2006;176:394-398.
71. Gelbard M, Lindner A, Chvapil M, Kaufman J. Topical beta-aminopropionitrile in the treatment of Peyronie's disease. J Urol. 1983;129:746-748.
72. Miller HC, Ardizzone J. Peyronie disease treated with ultrasound and hydrocortisone. Urology. 1983;21:584-585.
73. Martin DJ, Badwan K, Parker M, Mulhall JP. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol. 2002;168:2483-2485.
74. Fitch W, 3rd, Easterling WJ, Talbert RL, Bordovsky MJ, Mosier M. Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie's disease--a placebo-controlled pilot study. J Sex Med. 2007;4:477-484.
75. Singh J, Maibach HI. Topical iontophoretic drug delivery in vivo: historical development, devices and future perspectives. Dermatology. 1993;187:235-238.
76. Levine LA, Estrada CR, Shou W, Cole A. Tunica albuginea tissue analysis after electromotive drug administration. J Urol. 2003;169:1775-1778.
77. Riedl CR, Plas E, Engelhardt P, Daha K, Pfluger H. Iontophoresis for treatment of Peyronie's disease. J Urol. 2000;163:95-99.
78. Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Giurioli A, Jannini EA, Vespasiani G. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. J Urol. 2004;171:1605-1608.
79. Di Stasi SM, Giannantoni A, Capelli G, et al. Transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. BJU Int. 2003;91:825-829.
80. Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie's disease: a double-blind, placebo controlled trial. J Urol. 2007;177:972-975.
81. Skolarikos A, Alargof E, Rigas A, Deliveliotis C, Konstantinidis E. Shockwave therapy as first-line treatment for Peyronie's disease: a prospective study. J Endourol. 2005;19:11-14.
82. Srirangam SJ, Manikandan R, Hussain J, Collins GN and O'Reilly PH. Long-term results of extracorporeal shockwave therapy for Peyronie's disease. J Endourol. 2006;20:880-884.
83. Michel MS, Ptaschnyk T, Musial A, et al. Objective and subjective changes in patients with Peyronie's disease after management with shockwave therapy. J Endourol. 2003;17:41-44; discussion 44.
84. Strebel RT SS, Sautter T, Hauri D. Extracorporeal shock wave therapy for Peyronie's disease does not correct penile deformity. Int J Impot Res. 2004;16:448-451.
85. Hauck EW, Hauptmann A, Bschleipfer T, Schmelz HU, Altinkilic BM, Weidner W. Questionable efficacy of extracorporeal shock wave therapy for Peyronie's disease: results of a prospective approach. J Urol. 2004;171:296-299.
86. Hauck EW, Mueller UO, Bschleipfer T, Schmelz HU, Diemer T, Weidner W. Extracorporeal shock wave therapy for Peyronie's disease: exploratory meta-analysis of clinical trials. J Urol. 2004;171:740-745.
87. Chitale S, Morsey M, Swift L, Sethia K. Limited shock wave therapy vs sham treatment in men with Peyronie's disease: results of a prospective randomized controlled double-blind trial. BJU Int. 2010;106:1352-1356.
88. Palmieri A, Imbimbo C, Longo N, et al. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease. Eur Urol. 2009;56:363-369.
89. Hauck EW, Diemer T, Schmelz HU, Weidner W. A critical analysis of nonsurgical treatment of Peyronie's disease. Eur Urol. 2006;49:987-997.
90. Taylor FL, Levine LA. Non-surgical therapy of Peyronie's disease. Asian J Androl. 2008;10:79-87.
91. Levine LA, Newell M, Taylor FL. Penile traction therapy for treatment of Peyronie's disease: a single-center pilot study. J Sex Med. 2008;5:1468-1473.
92. Gontero P, Di Marco M, Giubilei G, et al. Use of penile extender device in the treatment of penile curvature as a result of Peyronie's disease. Results of a phase II prospective study. J Sex Med. 2009;6:558-566.
93. Raheem AA, Garaffa G, Raheem TA, et al. The role of vacuum pump therapy to mechanically straighten the penis in Peyronie's disease. BJU Int. 2010;106:1178-1180.
94. Ralph DJ. Long-term results of the surgical treatment of Peyronie's disease with plaque incision and grafting. Asian J Androl. 2011;13:797.
95. Djinovic R. Penile corporoplasty in Peyronie's disease: which technique, which graft? Curr Opin Urol. 2011;21:470-477.
96. Taylor FL, Levine LA. Surgical correction of Peyronie's disease via tunica albuginea plication or partial plaque excision with pericardial graft: long-term follow up. J Sex Med. 2008;5:2221-2228; discussion 2229-2230.
97. Serefoglu EC, Hellstrom WJ. Treatment of Peyronie's Disease: 2012 Update. Curr Urol Rep. 2011;12:444-452.
98. Kadioglu A, Kucukdurmaz F, Sanli O. Current status of the surgical management of Peyronie's disease. Nat Rev Urol. 2011;8:95-106.
99. Essed E, Schroeder FH. New surgical treatment for Peyronie disease. Urology. 1985;25:582-587.
100. Yachia D. Modified corporoplasty for the treatment of penile curvature. J Urol. 1990;143:80-82.
101. Daitch JA, Angermeier KW, Montague DK. Modified corporoplasty for penile curvature: long-term results and patient satisfaction. J Urol. 1999;162:2006-2009.
102. Rehman J, Benet A, Minsky LS, Melman A. Results of surgical treatment for abnormal penile curvature: Peyronie's disease and congenital deviation by modified Nesbit plication (tunical shaving and plication). J Urol. 1997;157:1288-1291.
103. Ralph DJ, al-Akraa M, Pryor JP. The Nesbit operation for Peyronie's disease: 16-year experience. J Urol. 1995;154:1362-1363.
104. Gholami SS, Lue TF. Correction of penile curvature using the 16-dot plication technique: a review of 132 patients. J Urol. 2002;167: 2066-2069.
105. Syed AH, Abbasi Z, Hargreave TB. Nesbit procedure for disabling Peyronie's curvature: a median follow-up of 84 months. Urology. 2003;61:999-1003.
106. Savoca G, Scieri F, Pietropaolo F, Garaffa G, Belgrano E. Straightening corporoplasty for Peyronie's disease: a review of 218 patients with median follow-up of 89 months. Eur Urol. 46: 2004;610-614; discussion 613-614.
107. Rolle L, Tamagnone A, Timpano M, Destefanis P, Fiori C, Ceruti C, Fontana D. The Nesbit operation for penile curvature: an easy and effective technical modification. J Urol. 2005;173:171-173; discussion 173-174.
108. Bella AJ, Beasley KA, Obied A, Brock GB. Minimally invasive intracorporeal incision of Peyronie's plaque: initial experiences with a new technique. Urology. 2006;68:852-857.
109. Greenfield JM, Lucas S, Levine LA. Factors affecting the loss of length associated with tunica albuginea plication for correction of penile curvature. J Urol. 175: 2006;175:238-241.
110. Richardson B, Pinsky MR, Hellstrom WJ. Incision and grafting for severe Peyronie's disease (CME). J Sex Med. 2009;6:2084-2087; quiz 2088.
111. Moncada-Iribarren I JJ, Martinez-Salamanca JI, Cabello R, Hernandez C. Managing penile shortening after Peyronie's disease surgery. J Urol. 2007;177:252.
112. Dublin N, Stewart LH. Oral complications after buccal mucosal graft harvest for urethroplasty. BJU Int. 2004;94:867-869.
113. Santucci RA, Barber TD. Resorbable extracellular matrix grafts in urologic reconstruction. Int Braz J Urol. 2005;31:192-203.
114. Sievert KD, Tanagho EA. Organ-specific acellular matrix for reconstruction of the urinary tract. World J Urol. 2000;18:19-25.
115. Breyer BN, Brant WO, Garcia MM, Bella AJ, Lue TF. Complications of porcine small intestine submucosa graft for Peyronie's disease. J Urol. 2007;177:589-591.
116. Tornehl CK, Carson CC. Surgical alternatives for treating Peyronie's disease. BJU Int. 2004;94:774-783.
117. Kendirci M, Hellstrom WJ. Critical analysis of surgery for Peyronie's disease. Curr Opin Urol. 2004;14:381-388.
118. Leungwattanakij S, Bivalacqua TJ, Reddy S, Hellstrom WJ. Long-term follow-up on use of pericardial graft in the surgical management of Peyronie's disease. Int J Impot Res. 2001;13:183-186
119. Mulhall J, Anderson M, Parker M. A surgical algorithm for men with combined Peyronie's disease and erectile dysfunction: functional and satisfaction outcomes. J Sex Med. 2005;2:132-138.
120. Wilson SK, Delk JR 2nd. A new treatment for Peyronie's disease: modeling the penis over an inflatable penile prosthesis. J Urol. 1994;152:1121-1123.
121. Wilson SK, Cleves MA, Delk JR, 2nd. Long-term followup of treatment for Peyronie's disease: modeling the penis over an inflatable penile prosthesis. J Urol. 2001;165:825-829.